The injectable drug delivery devices market was valued at USD 19.63 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 11.26%, reaching around USD 37.22 billion by 2030. This growth is primarily fueled by the increasing prevalence of chronic conditions such as cancer, diabetes, and cardiovascular diseases. Other factors driving market expansion include rising demand for self-injection devices, growth in the biologics and biosimilars sector, greater focus on patient adherence to therapies, and ongoing innovations in drug delivery technologies.
DelveInsight’s Injectable Drug Delivery Devices Market Insights report offers a comprehensive analysis of the current and projected market, detailing leading companies’ market shares, challenges, drivers, barriers, trends, and key players operating in this space.
Request for a sample report @ https://www.delveinsight.com/report-store/injectable-drug-delivery-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the Injectable Drug Delivery Devices Market Report
The Injectable Drug Delivery Devices market is expected to grow at a moderate CAGR between 2025 and 2032. According to DelveInsight, North America is likely to hold a leading share of the global market during this period.
Key players operating in the market include Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, and several others.
Significant developments in the market include:
-
On November 13, 2024, Simulations Plus, Inc. received a U.S. FDA grant to use physiologically based pharmacokinetic (PBPK) modeling via its GastroPlus® platform to develop and validate mechanistic in vitro-in vivo correlations (IVIVCs) for long-acting injectable (LAI) technologies, in collaboration with the University of Connecticut’s School of Pharmacy.
-
On August 21, 2022, Zydus Cadila obtained approval from India’s Drug Controller General (DCGI) for its needle-free, plasmid DNA-based COVID-19 vaccine.
-
On November 13, 2019, Stevanato Group partnered with Duoject to produce and promote the ‘Maverick’ auto-injector for emergency use.
-
On October 21, 2019, Becton Dickinson and Company launched the BD Intevia™ 1mL two-step disposable autoinjector, combining an autoinjector with a pre-fillable syringe into a single integrated system.
To read more about the latest highlights related to the Injectable Drug Delivery Devices market, get a snapshot of the key highlights entailed in the Global Injectable Drug Delivery Devices Market Report https://www.delveinsight.com/sample-request/injectable-drug-delivery-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Injectable Drug Delivery Devices Overview
Injectable drug delivery devices are medical instruments used to deliver medications directly into the body through injections. They are essential for administering various treatments, including biologics, vaccines, insulin, and chemotherapy drugs, particularly for managing chronic and acute conditions like diabetes, cancer, and cardiovascular disorders.
Injectable Drug Delivery Devices Market Insights
North America is expected to dominate the injectable drug delivery devices market, driven by the rising prevalence of chronic diseases, active research and development efforts, government initiatives promoting awareness of chronic conditions, and increasing healthcare spending. These factors are anticipated to strongly support market growth throughout the forecast period.
In the U.S., the American Cancer Society reported approximately 1.9 million new cancer cases in 2021, while CDC data recorded 1,752,735 new cases in 2019. Globocan 2021 noted around 61,152 new leukemia cases, 73,652 non-Hodgkin lymphoma cases, and 8,107 Hodgkin lymphoma cases in 2020.
Additionally, the American Heart Association projected that by 2035, over 130 million U.S. adults will be living with some form of heart disease.
This large patient population is expected to drive a significant increase in demand for injectable drug delivery devices in the United States over the coming years.
To know more about why North America is leading the market growth in the Injectable Drug Delivery Devices market, get a snapshot of the Injectable Drug Delivery Devices Market Outlook
Injectable Drug Delivery Devices Market Dynamics
According to the World Health Organization (2022), in 2020 there were approximately 2.26 million breast cancer cases, 2.21 million lung cancer cases, 1.93 million colorectal cancer cases, 1.41 million prostate cancer cases, and 1.09 million stomach cancer cases reported globally. The International Diabetes Federation’s Diabetes Atlas (2022) estimated that 537 million adults were living with diabetes in 2021, with projections increasing to 643 million by 2030 and 783 million by 2045.
The British Heart Foundation (2022) also reported that in 2019, roughly 550 million people worldwide—about 1 in 14—were affected by heart and circulatory diseases, including around 290 million women and 260 million men.
The rising global prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders has led to a greater demand for effective treatment options, increasing the frequency of procedures like chemotherapy and insulin administration. This trend is driving the growth of the injectable drug delivery market, as these systems provide targeted, efficient, and precise drug delivery, which is critical for managing complex, long-term conditions.
Moreover, innovations such as needle-free injectors, prefilled syringes, auto-injectors, and microneedle systems are improving patient convenience, accuracy, and adherence to treatment, further accelerating market expansion.
Injectable Drug Delivery Devices Market Drivers:
-
Increasing incidences of chronic conditions such as cancer, diabetes, and cardiovascular disorders among others
-
Increase in demand for self-injectors
-
Increase in the biologics and biosimilar market
-
Rising need and demand for patient compliance to treatment
-
Rising innovations and technological advancement in this arena
Get a sneak peek at the Injectable Drug Delivery Devices market dynamics @ https://www.delveinsight.com/sample-request/injectable-drug-delivery-devices-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Coverage: Global
Study Period: 2022 to 2032
Key Injectable Drug Delivery Devices Companies: Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, and others.
Which MedTech key players in the Injectable Drug Delivery Devices market are set to emerge as the trendsetter, explore @ Injectable Drug Delivery Devices Companies
Table of Contents
1. Injectable Drug Delivery Devices Market Report Introduction
2. Injectable Drug Delivery Devices Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Injectable Drug Delivery Devices Market Key Factors Analysis
6. Injectable Drug Delivery Devices Market Porter’s Five Forces Analysis
7. Injectable Drug Delivery Devices Market Layout
8. Injectable Drug Delivery Devices Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us
About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/